Chronic idiopathic urticaria (CIU)/chronic spontaneous urticaria (CSU) is a condition characterized by spontaneous appearance of pruritic hives, angioedema, or both that recur without an identifiable external cause and persist for 6 weeks or longer.
1-3 CIU/CSU is a rare condition, and its prevalence was reported to range between 0.6% and 0.8% in the general population of Spain and Germany. 4, 5 Patients with CIU/CSU report substantial worsening of health-related quality of life. [6] [7] [8] The Urticaria Activity Score (UAS) is a validated measure to assess disease activity in patients with CIU/CSU. The UAS score (range, 0-6) comprises a sum of daily ratings for itch severity and number of hives (0-3 points for each). The weekly Urticaria Activity Score (UAS7) sums UAS scores during a 7-day period, and possible values for the UAS7 range from 0 to 42. US and European guidelines recommended evaluating disease activity and response to treatment in routine clinical practice. 2, 3 The 2014 CIU/CSU guidelines for the United States and Europe 2, 3 recommend treating CIU/CSU in a stepwise manner, starting with 
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CIU: Chronic idiopathic urticaria CSU: Chronic spontaneous urticaria LTRA: Leukotriene receptor antagonist UAS: Urticaria Activity Score UAS7: Weekly Urticaria Activity Score monotherapy with a second-generation antihistamine. 2, 3 However, complete response to H 1 -antihistamines has been reported to reach slightly greater than 50% in patients with CIU/CSU. 1 Although the next steps vary slightly between guidelines, recommendations include increasing the dose of H 1 -antihistamine up to 4-fold and/or adding other therapies, such as H 2 -antihistamines or leukotriene receptor antagonists (LTRAs). Should lack of control continue, guidelines recommend using omalizumab. 2, 3 Data from 3 phase III clinical trials (ASTERIA I, ASTERIA II, and GLACIAL) demonstrated the efficacy and safety of omalizumab to treat patients with CIU/CSU. [9] [10] [11] Despite the positive results of these trials, many clinical questions remain regarding the response to omalizumab in patients with CIU/CSU. The expected timing of response to omalizumab has not been previously reported. Furthermore, published data do not provide guidance on how many doses might be needed to define response or lack of response.
The aim of this analysis was to investigate response patterns of omalizumab to treat CIU/CSU in the phase III clinical trial data, with a goal of providing a practical approach to omalizumab use for clinicians by using omalizumab in the real-world setting.
METHODS
Phase III omalizumab studies ASTERIA I, 11 ASTERIA II, 10 and GLACIAL 9 were phase III, global, randomized, multicenter, double-blind, placebo-controlled clinical trials designed to assess the efficacy and safety of omalizumab use in patients with CIU/CSU. ASTERIA I and ASTERIA II enrolled patients with CIU/CSU who remained symptomatic despite treatment with H 1 -antihistamines at approved doses. Enrolled patients in both studies had to have a UAS7 > _ 16 (equivalent to moderate-to-severe CIU/CSU symptoms on at least 4 of 7 days 2 ) and an itch component UAS7 (range, 0-21) > _ 8 for the 7 days before randomization. Enrolled patients were randomized 1:1:1:1 to receive omalizumab (75, 150, or 300 mg) or placebo subcutaneously every 4 weeks for 6 (ASTERIA I) or 3 (ASTERIA II) doses. In both studies, patients were observed for an additional 16 weeks without therapy. In ASTERIA I, patients were allowed to change their background medication after week 12. The primary efficacy end point in both studies assessed the mean change in weekly itch severity score from baseline to week 12. The studies also evaluated the proportion of patients who achieved well-controlled urticaria (UAS7 < _ 6; secondary analysis in both studies) and the proportion of patients who achieved complete response (UAS7 5 0; secondary analysis in ASTERIA I and post hoc analysis in ASTERIA II) at week 12. Additional details of the ASTERIA I and ASTERIA II study designs have been published elsewhere. 10, 11 GLACIAL was a phase III, global, randomized, multicenter, double-blind, placebo-controlled clinical trial that assessed the safety and efficacy of omalizumab use in patients with CIU/CSU. H 1 -antihistamines had failed at up to 4 times the recommended dose plus H 2 -antihistamines, LTRAs, or both in GLACIAL-enrolled patients. Enrolled patients were randomized 3:1 to receive 300 mg of omalizumab or placebo subcutaneously every 4 weeks for 6 doses. The primary end point in this study was the safety of 300 mg of omalizumab versus placebo. The key efficacy end point included the change in the weekly itch severity score from baseline to week 12, the proportion of patients with well-controlled urticaria (UAS7 < _ 6) at week 12, and the proportion of patients with complete response (UAS7 5 0) at week 12. Additional details of the GLACIAL study design have been published by Kaplan et al. 9 All 3 studies were conducted in accordance with US Food and Drug Administration regulations, the International Conference on Harmonisation E6 Guideline for Good Clinical Practice, and any other applicable laws. Institutional review board approval and informed consent were obtained from all patients. These trials are registered with ClinicalTrials.gov (no. NCT01287117 for ASTERIA I, no. NCT01292473 for ASTERIA II, and no. NCT01264939 for GLACIAL).
Data collection and assessments
Patients used an electronic handheld device (eDiary) to record data twice daily for the validated Urticaria Patient Daily Diary. [12] [13] [14] These data informed the primary and many secondary end points from study patients in all 3 phase III studies of omalizumab. The Urticaria Patient Daily Diary includes questions about itch severity and number of hives (to assess UAS), largest hive size, sleep interference, daily activity interference, diphenhydramine (rescue medication use), angioedema episodes and management, and health provider contact for CIU/CSU-related issues. Patients reported itch severity twice daily on a scale from 0 to 3 (0, none; 1, mild; 2, moderate; and 3, severe).-Patients also reported the number of hives twice daily on a scale from 0 to 3 (0, none; 1, between 1 and 6 hives; 2, between 7 and 12 hives; and 3, >12 hives).
Definitions of response
The following definitions of response to treatment were based on the UAS7: either complete response (itch and hive free, UAS7 5 0) or well-controlled urticaria (UAS7 < _ 6). By design, the well-controlled urticaria group also included complete responders. BMI, Body mass index; CU, chronic urticaria. *Individual study baseline characteristics by dose group have previously been published. [9] [10] [11] ASTERIA I (n 5 313), ASTERIA II (n 5 314), pooled (n 5 627), and GLACIAL (n 5 329). àThe CU Index reflects the ability of serum to induce histamine release in normal basophils: ASTERIA I (n 5 317), ASTERIA II (n 5 321), and GLACIAL (n 5 333).
§ASTERIA I (n 5 306), ASTERIA II (n 5 308), pooled (n 5 614), and GLACIAL (n 5 326).
Analyses
We calculated the percentage of patients who achieved responses at time points separated by 4-week increments, as well as the percentage of nonresponders at 12 weeks who responded by week 24. We computed the proportion of weeks in the active treatment period during which patients experienced their responses; this analysis was performed for all patients. We estimated the percentage of patients who achieved a response they later sustained through the end of the drug administration period. The x 2 test was used to compare all percentages in the conducted analyses. Median time to achieve first response was calculated using the Kaplan-Meier method; time to achieve first response was compared between treatment groups by using the log-rank test. All statistics were calculated with SAS 9.2 software (SAS A, ASTERIA I UAS7 < _ 6; B, ASTERIA I UAS7 5 0; C, ASTERIA II UAS7 < _ 6; D, ASTERIA II UAS7 5 0; E, GLACIAL UAS7 < _ 6; and F, GLACIAL UAS7 = 0. *P < .05 and **P < .001. OMA, Omalizumab.
Institute, Cary, NC). Missing UAS7 data at week 12 resulted in patients imputed as nonresponders.
RESULTS

Patient demographics
In the following 3 phase III studies of omalizumab in patients with CIU/CSU, a total of 975 patients were randomized and received at least 1 dose of study drug: ASTERIA I (75 mg of omalizumab (Table I) . [9] [10] [11] Most of the patients in each study were white, and the majority were female. The average age ranged from 41.2 years (ASTERIA I) to 43.1 years (GLACIAL), and the baseline Chronic Urticaria Index was negative (<10) for most patients (69% [GLACIAL] to 75% [ASTERIA I]). Patients' baseline characteristic data have been published elsewhere.
9-11
Responders
Response at different time points. At week 4, after a single dose of study drug, well-controlled urticaria (UAS7 < _ 6) was reported by 5%, 12%, 21%, and 37% of patients in ASTERIA I (placebo and 75, 150, or 300 mg of omalizumab, respectively); 13%, 15%, 28%, and 51% of patients in ASTERIA II (placebo and 75, 150, or 300 mg of omalizumab, respectively); and 2% and 37% of patients in GLACIAL (placebo and 300 mg of omalizumab, respectively). At week 4, a complete response (UAS7 5 0) was noted in 1%, 5%, 6%, and 19% of patients in ASTERIA I (placebo and 75, 150, or 300 mg of omalizumab, respectively); 0%, 4%, 6%, and 24% of patients in ASTERIA II (placebo and 75, 150, or 300 mg of omalizumab, respectively); and 0% and 15% of patients in GLACIAL (placebo and 300 mg of omalizumab, respectively). The percentage of well-controlled urticaria (UAS7 < _ 6) and complete responders (UAS7 5 0) during the active treatment period increased with continued dosing (Fig 1) . The 300-mg dose of omalizumab produced the highest response rates among all study arms.
Patients in ASTERIA I and GLACIAL continued to receive therapy beyond week 12. With continued dosing, some patients who had not met the definitions of response at week 12 met those definitions at week 24: ASTERIA I (45.7%, 34.4%, and 58.1%, respectively, of the 75-, 150-, and 300-mg arms and 38.2% of the placebo arm) and GLACIAL (48.9% in the 300-mg omalizumab arm and 14.3% in the placebo arm; Fig 2) .
Median time to achieve response. Of 12 weeks of active treatment (ASTERIA II), the median time to achieve well-controlled urticaria (UAS7 < _ 6) was 8, 7, and 3 weeks (75, 150, and 300 mg of omalizumab, respectively); fewer than 50% of placebo patients achieved a UAS7 < _ 6 within the first 12 weeks of active treatment, and therefore a median time to the end point could not be calculated. In the same study, median time to achieve complete response (UAS7 5 0) was 8 weeks for patients receiving 300 mg of omalizumab; fewer than 50% of patients in other treatment arms achieved a UAS7 5 0 within the 12-week period.
Of 24 weeks of treatment, the median time to achieve well-controlled urticaria (UAS7 < _ 6) was 11 and 6 weeks (150 and 300 mg of omalizumab, respectively; ASTERIA I) and 6 weeks (300 mg of omalizumab, GLACIAL; Fig 3) ; in other treatment arms, fewer than 50% of patients achieved the outcome by week 24. The median time to achieve complete response (UAS7 5 0) was 12 and 13 weeks (300 mg of omalizumab; ASTERIA I and GLACIAL, respectively; Fig 3) ; in other treatment arms fewer than 50% of patients achieved the outcome by week 24. Of the patients being treated with 300 mg of omalizumab who had not achieved well-controlled urticaria (UAS7 < _ 6) as of week 12, 58% achieved it between weeks 13 and 24. In contrast, of the patients receiving placebo who had not achieved well-controlled urticaria as of week 12, 38% achieved it between weeks 13 and 24.
Length of response. The proportion of weeks in the active treatment (the first 12 weeks in ASTERIA II and the first 24 weeks in ASTERIA I and GLACIAL) period during which patients experienced response was highest in the 300-mg omalizumab treatment arm (Fig 4) . To calculate this outcome, we summed the total number of weeks during which patients reported a response and divided it by the total number of patient-weeks in the arm. This effect was consistent in all 3 studies.
Sustained response. Sustained response was defined as instances when patients who achieved well-controlled urticaria (UAS7 < _ 6) or complete response (UAS7 5 0) maintained that response through the rest of the active treatment period (week 12 [ASTERIA II] and week 24 [ASTERIA I and GLACIAL]; Fig 5) . In the 300-mg omalizumab arms, more patients achieved sustained responses and did so earlier than patients in other treatment arms.
DISCUSSION
The results of this study illustrate the response patterns of patients with CIU/CSU treated with omalizumab. Complete response (UAS7 5 0) and achievement of well-controlled urticaria (UAS7 < _ 6) appeared early (before week 4) in some patients, and some patients continued to achieve response up to week 24. Some patients responded to treatment after the first injection; however, others took longer to respond. Indeed, the fact that some patients responded after week 12 suggests that stopping treatment before at least 3 omalizumab doses might miss an opportunity to bring their CIU/CSU symptoms under control. Overall, these results might help health care providers by setting expectations of likelihood of response at different time points after initiation of omalizumab. Despite different background therapies in GLACIAL, which allowed patients to receive higher doses of H 1 -antihistamines and other background therapies (H 2 blockers and LTRAs) than in ASTERIA I and II, patients' response patterns were comparable among the 3 studies analogous to the similarities in efficacy previously noted. 15 All studies had patients who responded after the first 3 doses. In all 3 studies, response manifested in a dose-dependent manner, with the likelihood of response increasing in patients receiving higher doses. Patients receiving 300 mg of omalizumab had a higher rate of response, and more of them sustained their response than in other treatment arms. Response patterns in weeks 13 to 24 were similar in ASTERIA I and GLACIAL.
The timing of well-controlled and complete response suggests that there might be 2 categories of responders to omalizumab: those who respond early (before week 4) and those who require more than 3 monthly doses to respond. The median time to complete response was observed between 8 and 10 weeks for 300 mg of omalizumab. Early onset of omalizumab efficacy has been reported in patients with CIU/CSU and other disease areas. Lin et al 16 followed 24 patients with adult allergic rhinitis treated with omalizumab (0.016 mg/kg per IgE [IU/mL]) or placebo for 6 weeks. Decreases in IgE levels were reported as early as 3 days in patients treated with omalizumab, and basophil FcεRI receptor activity was significantly reduced by day 7 and further decreased by day 42. 16 Pereira Santos et al 17 followed 2 patients with severe uncontrolled asthma who were given 300 mg of omalizumab every 2 weeks for 1 year; serial assessments of FcεRI expression on basophils were performed. The reduction in FcεRI expression was maximized mostly within the first month of treatment, although some additional small reductions were reported during the subsequent year of treatment. In the study by Metz et al, 18 30 adults with CIU/CSU were randomized to receive omalizumab or placebo every 4 weeks for 12 weeks. FcεRI 1 skin cell numbers decreased in omalizumab-treated patients by day 8 and continued to do so by day 85. 18 Metz et al 18 reported that among 51 patients with chronic urticaria, 12 gained complete response within 1 week, and 6 patients did so within 4 weeks of the first omalizumab injection. Although the early responders in our study follow these findings, the mechanism to explain the late responders is not completely clear.
Our findings of a subpopulation of patients with CIU/CSU with a late response to omalizumab concur with data published by Uysal et al. 19 The authors individualized omalizumab doses and dosing intervals to treat patients with different types of urticaria: CIU/CSU (85%), delayed pressure urticaria (22%), urticaria factitia (11%), contact urticaria (7%), and heat contact urticaria (7%). 19 This small single-arm open-label study included 27 patients with urticaria (aged 10-65 years) who were started on 150 mg of omalizumab. In 2 weeks, physicians evaluated each patient's condition and prescribed the next dose based on how the patient responded. Approximately 56% (15/27) of patients reached a UAS > 2 after a single 150-mg omalizumab dose and stayed in this dose category, and the remaining patients (12/27) received 300 mg of omalizumab at week 3 and remained in this dose category.
In the ''time to response'' analyses, after week 12, the Kaplan-Meier curves of the placebo and 300-mg omalizumab groups demonstrated apparently similar slopes. By week 12, many of the patients in the 300-mg omalizumab group had already achieved a response (well-controlled urticaria or complete response). Therefore, the group had begun to reach a ceiling beyond which further improvement was difficult. This was most noticeable in the patients who achieved well-controlled urticaria (UAS7 < _ 6). However, when examining only patients who had an opportunity for improvement, we see that the percentage of patients who had not achieved a UAS7 < _ 6 at week 12 but responded as such during weeks 13 to 24 was 58% in the 300-mg omalizumab group and 38% in the placebo group. The study was not powered to detect this end point of improvement after 12 weeks among patients not yet achieving response, and statistical tests comparing such end points were not performed among this small sample; thus we are not able to draw any strong conclusions regarding later responses to omalizumab.
Although the definitions of response were prespecified outcomes in ASTERIA I and II and GLACIAL, 9-11 the authors are not aware of any formal definition of response to treatment (with any medication) for patients with CIU/CSU. The state of well-controlled urticaria (UAS7 < _ 6) is a reasonable and clinically relevant threshold because it requires patients to be well-controlled with only minimal symptoms. Complete response (UAS7 5 0), which connotes complete elimination of itch and hives, stands out as an attractive clinical objective but is often difficult to achieve. Regardless of the responder definition, the 300-mg dose of omalizumab demonstrated the best outcomes. Therefore, it might be reasonable to initiate treatment with the 300-mg dose to ensure best outcomes for the patients.
Data from this analysis might inform decisions regarding an approach to evaluating response to omalizumab treatment. Knowledge of expected response to omalizumab therapy might assist prescribers in determining the length of a therapeutic trial and inform patients or prescribers as to what to expect from omalizumab therapy. Setting patients' expectations regarding the risks and benefits of a therapy can improve adherence to a treatment regimen and contribute to optimization of outcomes. 20 Continued investigation into time to response, identification of specific phenotypes in response to omalizumab, and length of treatment will be important to prescribers who have patients who require omalizumab for management of CIU/CSU. Improving our understanding of the activity of omalizumab in the inflammatory process associated with symptomatic CIU/CSU and recognizing that a subset of patients might have a delay in response could also help to inform decisions regarding optimization of omalizumab therapy. Although phase III, randomized, double-blind, placebocontrolled trials remain the gold standard for establishing efficacy, the results of this analysis should be interpreted in light of its limitations. Clinical trial data were not available beyond week 24, and therefore information on the response to treatment beyond this time is unknown. Results from a phase II dose-ranging study -W24  W17-W20  W13-W16  W9-W12  W5-W8  W1-W4   W21-W24  W17-W20  W13-W16  W9-W12  W5-W8  W1-W4   W21-W24  W17-W20  W13-W16  W9-W12  W5-W8  W1-W4   W21-W24  W17-W20  W13-W16  W9-W12  W5-W8  W1- provided the framework for the flat dosing (non-IgE and non-weight-based dosing) and 4-week interval used in the pivotal studies. 21 Despite evidence from the phase II and 3 phase III proof-of-concept studies, [9] [10] [11] it must be acknowledged that we still have much to learn about optimal dosing of omalizumab in patients with CIU/CSU. On the basis of Genentech's data on file, we also know that the patients in the placebo arm used more background therapy than patients in the omalizumab arm. Therefore, such misbalance is likely to have unfavorably affected omalizumab arms, as opposed to the placebo arm. In addition, these studies permitted the use of rescue medication (diphenhydramine), and our analysis did not control for rescue medication use. Finally, the comparison arm of these studies included placebo plus standard of care and thus was not a pure untreated placebo arm.
Although this study highlighted 2 categories of responders (ie, early and late) the exact mechanisms responsible for these responses are not completely clear. In addition, some patients experienced relapse of their symptoms during either the treatment or follow-up periods. Understanding patterns in relapses might help physicians effectively dose omalizumab in their practice, although relapse analysis was outside the scope of this study. Further research is needed to understand characteristics predictive of early versus late response, as well as relapse patterns in patients with CIU/CSU treated with omalizumab.
In summary, response patterns to treatment of CIU/CSU with omalizumab were dose dependent; use of the 300-mg dose of omalizumab resulted in the largest percentage of patients who achieved a complete response (UAS7 5 0) or well-controlled urticaria (UAS7 < _ 6). Half of the patients treated with 300 mg of omalizumab had well-controlled symptoms after 2 injections (median time to response, 6 weeks). The benefits of omalizumab treatment in patients with CIU/CSU were evident to week 24. These data highlight the likelihood of response to omalizumab in patients with CIU/CSU at different time points and will help prescribers set patients' expectations for therapy.
